TST 10088

Drug Profile

TST 10088

Alternative Names: TST 88; TST10088

Latest Information Update: 28 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Twinstrand Therapeutics
  • Developer Emergent BioSolutions
  • Class Antineoplastics; Proteins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
  • 07 Jul 2009 Twinstrand Therapeutics has been acquired and merged into Cangene-Corporation
  • 07 Jul 2009 Twinstrand Therapeutics has been acquired by Cangene Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top